Dr Cory Lappin, OD, MS, FAAO, presents this clinical research summary video examining improvement in visual tasking activities and workplace productivity after 14 days of Acoltremon 0.0003% treatment…

Watch the case study for Results of Phase 3 Studies for Acoltremon Ophtalmic Solution 0.003%, a Novel TRPM8 Agonist.

Study Objectives and Assessments: Comet-1: Evaluate the safety and efficacy of two doses of topical ophthalmic AR-15512 compared with vehicle in subjects with DED (Phase 2b); Comet-2&3: Evaluate…